Literature DB >> 10619823

Severe pulmonary hypertension in histiocytosis X.

M Fartoukh1, M Humbert, F Capron, S Maître, F Parent, C Le Gall, O Sitbon, P Hervé, P Duroux, G Simonneau.   

Abstract

Diminished exercise capacity in advanced pulmonary histiocytosis X does not appear to be related to ventilatory limitation but may be related to pulmonary vascular dysfunction. Pulmonary hemodynamics and respiratory function were studied in 21 consecutive patients with advanced pulmonary histiocytosis X, and compared with parameters of patients with other severe chronic lung diseases (29 patients with chronic obstructive pulmonary disease and 14 patients with idiopathic pulmonary fibrosis). All patients with pulmonary histiocytosis X displayed severe pulmonary hypertension: mean pulmonary arterial pressure, 59 +/- 4 mm Hg; cardiac index, 2.6 +/- 0.8 L/min/m(2); and total vascular pulmonary resistance, 25 +/- 3 IU/m(2) (p < 0.05, as compared with patients with other chronic lung diseases). Pa(O(2)) was similar in the three groups, whereas FEV(1) was lower in patients with other chronic lung diseases (p < 0.05). In contrast to other chronic lung diseases, the degree of pulmonary hypertension was not related to variables of pulmonary function in pulmonary histiocytosis X. Histopathology was available for 12 patients with pulmonary histiocytosis X and revealed proliferative vasculopathy involving muscular arteries and veins, with prominent venular involvement. Two consecutive lung samples (taken before and after the occurrence of pulmonary hypertension) were available for six patients with pulmonary histiocytosis X, and showed that pulmonary vasculopathy worsened, whereas parenchymal and bronchiolar lesions remained relatively unchanged. These results indicate that pulmonary hypertension in pulmonary histiocytosis X might be related to an intrinsic pulmonary vascular disease, in which the pulmonary circulation is involved independent of small airway and lung parenchyma injury.

Entities:  

Mesh:

Year:  2000        PMID: 10619823     DOI: 10.1164/ajrccm.161.1.9807024

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  29 in total

Review 1.  Rare lung diseases III: pulmonary Langerhans' cell histiocytosis.

Authors:  Stephen C Juvet; David Hwang; Gregory P Downey
Journal:  Can Respir J       Date:  2010 May-Jun       Impact factor: 2.409

Review 2.  CT imaging of peripheral pulmonary vessel disease.

Authors:  Arnaud Resten; Sophie Maitre; Dominique Musset
Journal:  Eur Radiol       Date:  2005-05-20       Impact factor: 5.315

Review 3.  Rare causes of pulmonary hypertension: spectrum of radiological findings and review of the literature.

Authors:  Alice Rossi; Maurizio Zompatori; Patrick Tchouante Tchouanhou; Michele Amadori; Massimiliano Palazzini; Elisa Conficoni; Nazzareno Galiè; Venerino Poletti; Giampaolo Gavelli
Journal:  Radiol Med       Date:  2013-11-15       Impact factor: 3.469

Review 4.  Cardiothoracic manifestations of primary histiocytoses.

Authors:  Daniel Vargas; J Caleb Richards; Daniel Ocazionez; Arlene Sirajuddin; Lorna Browne; Carlos S Restrepo
Journal:  Br J Radiol       Date:  2016-09-26       Impact factor: 3.039

5.  High-resolution chest CT findings do not predict the presence of pulmonary hypertension in advanced idiopathic pulmonary fibrosis.

Authors:  David A Zisman; Arun S Karlamangla; David J Ross; Michael P Keane; John A Belperio; Rajan Saggar; Joseph P Lynch; Abbas Ardehali; Jonathan Goldin
Journal:  Chest       Date:  2007-06-15       Impact factor: 9.410

6.  Pulmonary hypertension associated with lung transplantation obliterative bronchiolitis and vascular remodeling of the allograft.

Authors:  R Saggar; D J Ross; R Saggar; D A Zisman; A Gregson; J P Lynch; M P Keane; S Samuel Weigt; A Ardehali; B Kubak; C Lai; D Elashoff; M C Fishbein; W D Wallace; J A Belperio
Journal:  Am J Transplant       Date:  2008-07-28       Impact factor: 8.086

Review 7.  Group 5 Pulmonary Hypertension: The Orphan's Orphan Disease.

Authors:  Sara Kalantari; Mardi Gomberg-Maitland
Journal:  Cardiol Clin       Date:  2016-08       Impact factor: 2.213

Review 8.  [Interstitial lung diseases and pulmonary hypertension].

Authors:  H P Hauber
Journal:  Internist (Berl)       Date:  2009-09       Impact factor: 0.743

Review 9.  Cigarette smoking and diffuse lung disease.

Authors:  Rajesh R Patel; Jay H Ryu; Robert Vassallo
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 10.  Challenges in pulmonary fibrosis. 3: Cystic lung disease.

Authors:  Gregory P Cosgrove; Stephen K Frankel; Kevin K Brown
Journal:  Thorax       Date:  2007-09       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.